Conflict of interest in the debate over calcium-channel antagonists

New England Journal of Medicine

Volumn 338, Issue 2, 1998, Pages 101-106

  Stelfox, Henry Thomas ^a   Chua, Grace ^a   O'Rourke, Keith ^b   Detsky, Allan S ^a,b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE;

ARTICLE; DRUG INDUSTRY; DRUG SAFETY; FINANCIAL MANAGEMENT; HUMAN; MEDICAL EDUCATION; MEDICAL ETHICS; MEDICAL LITERATURE; MEDICAL RESEARCH; NORMAL HUMAN; POLICY; PRIORITY JOURNAL;

BIOMEDICAL RESEARCH; CANADA; CLINICAL APPROACH/SOURCE; EDITORIAL POLICIES; EMPIRICAL APPROACH; HEALTH CARE AND PUBLIC HEALTH; RISKS AND BENEFITS; SURVEY; UNITED STATES;

BIOMEDICAL RESEARCH; CALCIUM CHANNEL BLOCKERS; CONFLICT OF INTEREST; DISCLOSURE; DRUG INDUSTRY; EDITORIAL POLICIES; HUMANS; PHYSICIANS; RESEARCH SUPPORT; RISK ASSESSMENT;

EID: 0032495544     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199801083380206     Document Type: Article

References (86)

1. Psaty BM, Heckbert SR, Koepsell TD, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274: 620-5.
2. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92: 1326-31.
3. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.
4. Chren M, Landefeld C. Physicians' behavior and their interactions with drug companies: a controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994;271:684-9.
5. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA 1990;264:1693-7.
6. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns: there's no such thing as a free lunch. Chest 1992;102:270-3.
7. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
8. Macdonald G. Are calcium antagonists safe? Lancet 1995;346:768.
9. Schubert T. Risks and benefits of calcium antagonists. Lancet 1995; 346:961.
10. Horton R. Bayer accused of disinformation. Lancet 1995;346:891-2.
11. Barnett AA. FDA committee rules calcium-channel blockers safe. Lancet 1996;347:313.
12. Marwick C. FDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996;275:423-4. [Erratum, JAMA 1996;275:1638.]
13. MacCarthy EP. Dear doctor . . . regarding calcium channel blockers. JAMA 1996;275:518.
14. Calcium-channel blockers: managing uncertainty. Lancet 1996;348: 487.
15. Dargie HJ. Calcium-channel blockers and the clinician. Lancet 1996; 348:488-9. [Erratum, Lancet 1996;348:694.]
16. Stryer DB, Lurie P, Bero LA. Dear doctor . . . regarding calcium channel blockers. JAMA 1996;275:517.
17. Walker AM, Stampfer MJ. Observational studies of drug safety. Lancet 1996;348:489.
18. Lip GYH, Beevers DG. Antagonism to calcium antagonists. Lancet 1996;347:1761.
19. Goodman S. Update on the calcium antagonist controversy: the Furberg meta-analysis revisited: scientific update. No. 120-06. Toronto: St. Michael's Hospital Division of Cardiology, 1996.
20. Fagan TC. Calcium antagonists and mortality: another case of the need for clinical judgment. Arch Intern Med 1995;155:2145.
21. Buring JE, Glynn RJ, Hennekens CN. Myocardial infarction associated with antihypertensive drug therapy. JAMA 1996;275:517
22. Poole-Wilson PA. Are calcium antagonists safe? Lancet 1995;346:769-70.
23. Walker AM, Johnson ES. Bias in case-control studies of calcium antagonists. Am J Cardiol 1996;78:380.
24. Ferrari R. Prognosis of patients with unstable angina or acute myocardial infarction treated with calcium channel antagonists. Am J Cardiol 1996;77:22D-25D.
25. Mehta JL, Subramanian VB. Calcium blockers and risk of myocardial infarction and coronary heart disease mortality. Circulation 1996;93:1472.
26. Opie LH. Risks and benefits of calcium antagonists. Lancet 1995;346: 961.
27. Frohlich ED, Zanchetti A. Antihypertensive therapy: safety and efficacy of drugs and publications. Hypertension 1996;27:317-8.
28. Gordon RD. Calcium antagonists and gastrointestinal haemorrhage: the balancing act. Lancet 1996;347:1056.
29. Smith GN. Calcium channel blockers and myocardial infarction. J Fam Pract 1996;42:30-2.
30. Horton R. Spinning the risks and benefits of calcium antagonists. Lancet 1995;346:586-7.
31. Ghali WA, Hershman WY. Meta-analysis and bouillabaisse. Ann Intern Med 1996;125:518-9.
32. Elliott HL, Epstein M, Haller H, Mancia G. Safety of calcium antagonists. Lancet 1995;346:1421.
33. Rafflenbeul W. Nifedipine trials. Circulation 1996;93:1473-4.
34. Feeman WE Jr. Myocardial infarction associated with antihypertensive drug therapy. JAMA 1996;275:515.
35. Parmley WW. A delayed answer to the calcium blocker question. J Am Coll Cardiol 1996;27:510-1. [Erratum, J Am Coll Cardiol 1996;27:1820.]
36. Habib GB. Arc calcium antagonists harmful in hypertensive patients? Distinguishing hype from reality. Chest 1995;108:3-5.
37. Kaplan NM. Do calcium antagonists cause myocardial infarction? Am J Cardiol 1996;77:81-2.
38. Frohlich ED. Recent media reports of potential risks from calcium antagonists. J La State Med Soc 1995;147:343.
39. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995;155:2150-6.
40. Tijssen JGP, Hugenholtz PG. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J 1996;17:1152-7.
41. Brown MJ. Are calcium antagonists safe? Lancet 1995;346:768-9.
42. Buring JE, Glynn RJ, Hennekens CH. Calcium channel blockers and myocardial infarction: a hypothesis formulated but not yet tested. JAMA 1995;274:654-5.
43. Mancia G, van Zwieten PA. How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996;14:13-7.
44. Messerli FH. Case-control study, meta-analysis, and bouillabaisse: putting the calcium antagonist scare into context. Ann Intern Med 1995;123: 888-9.
45. Pilotto A, Leandro G, Franceschi M, Di Mario F, Valerio G. Antagonism to calcium antagonists. Lancet 1996;347:1761-2.
46. Messerli FH, Opie LH, Chambers R. Long-term safety of calcium antagonists: reassessment of the Furberg hypothesis. J Am Coll Cardiol 1996; 27:Suppl A:319A. abstract.
47. Poole-Wilson PA. The calcium antagonist controversy; implications beyond drug prescription. Eur Heart J 1996;17:1131-3.
48. Rafflenbeul W. Nifedipine in acute coronary syndromes: Furberg's refrain revisited. Eur Heart J 1996;17:1147-52.
49. Phillips BG, MacFarlane LL, Carson DS. Calcium-channel blockers and risk of myocardial infarction - more hype than harm. Am J Health Syst Pharm 1995;52:1460-2.
50. Ryden L, Malmberg K. Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease: what is the best choice? Eur Heart J 1996;17:1-3.
51. Kaplan NM. Do calcium antagonists cause cancer? Lancet 1996;348:541.
52. Lucas BD Jr, Hilleman DE. Media sensationalism of clinical trials: freedom of information or potential for causing patient harm? Ann Pharmacother 1995;29:629-31.
53. Kaplan NM. Dear doctor . . . regarding calcium channel blockers JAMA 1996;275:518.
54. Lichtlen PR. Nifedipine study. Circulation 1996;93:1472.
55. Idem. Risks and benefits of calcium antagonists. Lancet 1995;346: 962.
56. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92: 1074-8.
57. Messerli FH. Are calcium antagonists safe? Lancet 1995;346:767-8.
58. Opie LH, Messerli FH. Nifedipine and mortality: grave defects in the dossier. Circulation 1995;92:1068-73.
59. Monge JC. Safety of antihypertensive therapies: a series of interactive panels - are calcium channel blockers safe? Scientific update. No. 120-13. Toronto: St. Michael's Hospital Division of Cardiology, 1996.
60. Messerli FH. Meta-analysis and bouillabaisse. Ann Intern Med 1996; 125:519.
61. Idem. Whatever happened to the calcium antagonist controversy? J Am Coll Cardiol 1996;28:12-3.
62. Furberg CD, Psaty BM. Nifedipine trials. Circulation 1996;93:1474.
63. Idem. Corrections to the nifedipine meta-analysis. Circulation 1996; 93:1475-6.
64. Idem. Nifedipine in patients with heart disease. Circulation 1996;93: 1473.
65. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996;17:1142-7.
66. Hardell L, Axelson O, Fredrikson M. Antihypertensive drugs and risk of malignant diseases. Lancet 1996;348:542.
67. Furberg CD, Psaty BM. Calcium antagonists: antagonists or protagonists of mortality in elderly hypertensives? J Am Geriatr Soc 1995;43:1309-10.
68. Horton R. Are calcium antagonists safe? Lancet 1995;346:770.
69. Furberg CD, Psaty BM. Should dihydropyridines be used as first-line drugs in the treatment of hypertension? The con side. Arch Intern Med 1995;155:2157-61.
70. Pahor M, Guralnik JM, Salive ME, Corti M-C, Havlik RJ. Do calcium antagonists cause cancer? Lancet 1996;348:541-2.
71. Cooper RS, Freeman V. Myocardial infarction associated with antihypertensive drug therapy. JAMA 1996;275:515-6.
72. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik RJ. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-5.
73. Cooper RS. Risks and benefits of calcium antagonists. Lancet 1995; 346:961.
74. Tierney WM. Meta-analysis and bouillabaisse. Ann Intern Med 1996; 125:519.
75. Pahor M, Guralnik JM, Ferrucci L, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7
76. Gifford RW Jr. Are calcium antagonists safe? Cleve Clin Med 1995;62: 348-50.
77. Yusuf S. Calcium antagonists in coronary artery disease and hypertension: time for reevaluation? Circulation 1995;92:1079-82.
78. Blandino DA. Myocardial infarction associated with antihypertensive drug therapy. JAMA 1996;275:516.
79. Psaty BM, Koepsell TD, Weiss NS, et al. Dear doctor . . . regarding calcium channel blockers. JAMA 1996;275:518-9.
80. Psaty BM, Heckbert SR, Koepsell TD, et al. Myocardial infarction associated with antihypertensive drug therapy. JAMA 1996;275:516.
81. Psaty BM, Sevick MA. Antagonism to calcium antagonists. Lancet 1996;347:1761.
82. Barlow RE, Bartholomew DJ, Bremner JM, Brunk HD. Statistical inference under order restrictions: the theory and application of isotonic regression. Chichester, England: John Wiley, 1972.
83. Cox DR, Snell EJ. Analysis of binary data. London: Chapman & Hall, 1989.
84. Agresti A. Categorical data analysis. New York: John Wiley, 1990.
85. S-PLUS guide to statistical and mathematical analysis. Seattle: Statistical Sciences, 1995.
86. Angell M, Kassirer JP. Editorials and conflicts of interest. N Engl J Med 1996;335:1055-60.